RT Journal Article
SR Electronic
T1 High-contrast in-vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.05.20028407
DO 10.1101/2020.03.05.20028407
A1 Kenji Tagai
A1 Maiko Ono
A1 Manabu Kubota
A1 Soichiro Kitamura
A1 Keisuke Takahata
A1 Chie Seki
A1 Yuhei Takado
A1 Hitoshi Shinotoh
A1 Yasunori Sano
A1 Kiwamu Matsuoka
A1 Hiroyuki Takuwa
A1 Masafumi Shimojo
A1 Manami Takahashi
A1 Kazunori Kawamura
A1 Tatsuya Kikuchi
A1 Maki Okada
A1 Haruhiko Akiyama
A1 Hisaomi Suzuki
A1 Mitsumoto Onaya
A1 Takahiro Takeda
A1 Kimihito Arai
A1 Nobutaka Arai
A1 Nobuyuki Araki
A1 Yuko Saito
A1 Yasuyuki Kimura
A1 Masanori Ichise
A1 Yutaka Tomita
A1 Ming-Rong Zhang
A1 Tetsuya Suhara
A1 Masahiro Shigeta
A1 Naruhiko Sahara
A1 Makoto Higuchi
A1 Hitoshi Shimada
YR 2020
UL http://medrxiv.org/content/early/2020/03/16/2020.03.05.20028407.abstract
AB Depositions of fibrillary tau protein aggregates are implicated in diverse tauopathies, including Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD). A panel of radiochemicals has enabled in-vivo positron emission tomography (PET) of AD tau pathologies composed of all six tau isoforms, while sensitive detection of FTLD tau inclusions, mostly consisting of tau isoforms with three or four repeat domains only, has been unsuccessful. Here, we generated an imaging probe, PM-PBB3, for capturing tau deposits with all isoform composites. In-vitro assays demonstrated the reactivity of this compound with tau pathologies in AD, four-repeat tauopathies such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), and three-repeat tauopathies represented by Pick’s disease (PiD). We could also utilize PM-PBB3 for bimodal, multiscale optical/PET imaging of a living murine tauopathy model. A subsequent clinical PET study revealed increased binding of radiolabeled 18F-PM-PBB3 in diseased patients, reflecting cortical-dominant AD and subcortical-dominant PSP tau topologies. Notably, the in-vivo reactivity of 18F-PM-PBB3 with three- and four-repeat tau lesions was strongly supported by neuropathological examinations of autopsied and biopsied brains derived from PiD, PSP and CBD patients who underwent PET scans. Finally, visual inspection of 18F-PM-PBB3-PET images was indicated to facilitate individually based identification of the neuropathological basis, composed of PSP, CBD and PiD, underlying the diverse clinical phenotypes of FTLD. Taking these findings together, we propose the new tau probe as a powerful tool for etiological, diagnostic and therapeutic PET assessments of the tau pathogenesis in AD and FTLD spectra at nonclinical and clinical levels.One Sentence Summary We developed a positron emission tomography probe for tau fibrils in an animal model and patients with Alzheimer’s disease and non-Alzheimer’s disease tauopathies with high contrast, enabling translational assessments of the tau pathogenesis and diagnostic evaluations of disease-specific and stage-dependent tau topologies on an individual basis.Competing Interest StatementM-R. Zhang, T. Suhara, M. Higuchi, and H. Shimada hold a patent on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672). All the other authors have no potential conflicts of interest to be disclosed.Clinical TrialUMIN-CTR; number 000030248Funding StatementThis study was supported in part by AMED under Grant Number JP18dm0207018, JP19dm0207072, JP18dk0207026, JP19dk0207049 to M. H., and by MEXT KAKENHI Grant Number JP16H05324 to M. H., JP18K07543 to H. Shimada, JP26117011 to N. S., and by JST CREST Grant Number JPMJCR1652 to M. Higuchi.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.